CNS Pharmaceuticals Inc.
Organization details
- Legal name
- CNS Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Nevada
- Headquarters city
- Houston
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CNSP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001729427
- EIN
- 82-2318545
Board of directors
-
Amy Mahery · DirectorSince 2024
-
Andrzej Andraczke · DirectorSince 2023
-
Bettina M. Cockroft · DirectorSince 2023
-
Carl Anthony Evans · DirectorSince 2023
-
Faith L. Charles · DirectorSince 2022
-
Jeffry R. Keyes · DirectorSince 2023
-
Jerzy Gumulka · DirectorSince 2023
-
John M. Climaco · Director · Chief Executive OfficerSince 2023
-
Michal Fisher · DirectorSince 2026
-
Rami Levin · Director · CEO and PresidentSince 2026
Chief executives
Director election results
Annual meeting of September 30, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.6%
-
96.1%
-
96.4%
-
97.5%
-
97.5%
-
97.5%
Board connections
3 of this board's directors also sit on 4 other boards. 4 are in the same sector.
-
Abeona Therapeutics Inc. Same sectorvia Faith L. Charles
-
Annexon Inc. Same sectorvia Bettina M. Cockroft
-
CDT Equity Inc. Same sectorvia Faith L. Charles
-
Moleculin Biotech Inc. Same sectorvia John M. Climaco
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $44,009
- 2 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 14, 2026 | Rami Levin Officer (CEO and President) | Option exercise | −4,750 | — | — |
| May 18, 2026 | Faith L. Charles Director | Open-market purchase | +7,100 | $4.79 | $34,009 |
| May 18, 2026 | Michal Fisher Director | Open-market purchase | +2,000 | $5.00 | $10,000 |
| Feb 1, 2024 | Jerzy Gumulka Director | Open-market purchase | +33,333 | $0.30 | $10,000 |
| Feb 1, 2024 | Carl Anthony Evans Director | Open-market purchase | +33,333 | $0.30 | $10,000 |
| Feb 1, 2024 | Downs Christopher Officer (Chief Financial Officer) | Open-market purchase | +66,666 | $0.30 | $20,000 |
| Feb 1, 2024 | John M. Climaco Director, Officer (Chief Executive Officer) | Open-market purchase | +166,666 | $0.30 | $50,000 |
| Aug 22, 2023 | Downs Christopher Officer (Chief Financial Officer) | Open-market purchase | +27,000 | $1.27 | $34,290 |
| Aug 16, 2023 | John M. Climaco Director, Officer (Chief Executive Officer) | Open-market purchase | +2,750 | $1.80 | $4,950 |
| Apr 28, 2023 | John M. Climaco Director, Officer (Chief Executive Officer) | Option exercise | +1,250 | — | — |
| Apr 28, 2023 | Downs Christopher Officer (Chief Financial Officer) | Option exercise | +521 | — | — |
| Apr 19, 2023 | Jerzy Gumulka Director | Open-market purchase | +2,500 | $1.70 | $4,250 |
| Apr 17, 2023 | Downs Christopher Officer (Chief Financial Officer) | Open-market purchase | +3,100 | $3.20 | $9,920 |
| Apr 12, 2023 | John M. Climaco Director, Officer (Chief Executive Officer) | Open-market purchase | +15,000 | $0.69 | $10,350 |
| Apr 10, 2023 | Jerzy Gumulka Director | Open-market purchase | +7,173 | $0.74 | $5,308 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about CNS Pharmaceuticals Inc.
Who is the CEO of CNS Pharmaceuticals Inc.?
Rami Levin has been CNS Pharmaceuticals Inc.'s CEO and President since January 2026.
How many directors are on CNS Pharmaceuticals Inc.'s board?
CNS Pharmaceuticals Inc.'s board has 10 directors: Amy Mahery, Andrzej Andraczke, Bettina M. Cockroft, Carl Anthony Evans, Faith L. Charles, Jeffry R. Keyes, Jerzy Gumulka, John M. Climaco, Michal Fisher and Rami Levin.
Are CNS Pharmaceuticals Inc. insiders buying or selling shares?
Over the last 12 months, CNS Pharmaceuticals Inc. insiders bought $44,009 of shares in 2 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="cns-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.